Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

Vitrolife AB (publ): Interim report Q3, 2025: Strong growth in Americas

Vitrolife
Ladda ner börsmeddelandet

Third quarter

  • Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local currencies excluding discontinued business* was 5%.
  • Sales per region, in local currencies, were -2% in EMEA, +4% excluding discontinued business, +11% in Americas and +1% in APAC.
  • Sales per product group, in local currencies excluding discontinued business, were +7 in Consumables, +8% in Technologies and +3% in Genetics.
  • Sales per product group, in local currencies, were +4% in Consumables, +8% in Technologies and 0% in Genetics.
  • Gross margin increased to 58.9% (58.6), explained by a favourable product mix despite negative currency impact.
  • Earnings before depreciation and amortisation (EBITDA) amounted to SEK 253 (289) million, resulting in an EBITDA margin of 30.3% (33.4), impacted by negative currency effect.
  • Operating cash flow amounted to SEK 255 (206) million.
  • Net income amounted to SEK 102 (116) million, resulting in earnings per share of SEK 0.75 (0.85).

First nine months

  • Sales of SEK 2,548 (2,650) million, 1% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -5%. Organic growth in local currencies excluding discontinued business was 4%.
  • Sales per region, in local currencies, were +1% in EMEA, +8% excluding discontinued business, +8% in Americas and -5% in APAC.
  • Sales per product group, in local currencies excluding discontinued business, were +7% in Consumables, -1% in Technologies and +3% in Genetics.
  • Sales per product group, in local currencies, were +4% in Consumables, -2% in Technologies and +1% in Genetics.
  • Gross margin decreased to 58.1% (58.6) negatively impacted by currency.
  • Earnings before depreciation and amortisation (EBITDA) amounted to SEK 753 (888) million, resulting in an EBITDA margin of 29.5% (33.5), significantly impacted by negative currency effect.
  • Operating cash flow amounted to SEK 475 (640) million.
  • Net income amounted to SEK 301 (375) million, resulting in earnings per share of SEK 2.23 (2.76).

Gothenburg, October 23, 2025
VITROLIFE AB (publ)

Bronwyn Brophy O'Connor, CEO

* Discontinued business refers to discontinued activities in certain markets in EMEA.

The information was submitted for publication, through the agency of the contact persons set out above, at "Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">"Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">23-10-2025 08:00 CET.

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.